Antifungal Pharmacokinetics and Pharmacodynamics
Open accessThe DOI matches its Crossref record; 244 of the 250 references it cites were found in a registry or an index.
Abstract
Successful treatment of infectious diseases requires choice of the most suitable antimicrobial agent, comprising consideration of drug pharmacokinetics (PK), including penetration into infection site, pathogen susceptibility, optimal route of drug administration, drug dose, frequency of administration, duration of therapy, and drug toxicity. Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy. Here the concepts of antifungal PK/PD studies are reviewed, with emphasis on methodology and application. The initial sections of this review focus on principles and methodology. Then the pharmacodynamics of each major antifungal drug class (polyenes, flucytosine, azoles, and echinocandins) is discussed. Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This has been attributed to non-mycologic causes such as host factors, immune status, and/or pharmacologic issues8.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
In the citing paper
“it leaves the polyene amphotericin B, which is toxic8, as the only treatment option for these infections.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
Citations
Cites
Items 201–244 of 244
Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Warn, P. A., & Hope, W. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01111-12 · Cited by 40 · cited 2×
“For example, a human cell culture with a bilayer of alveolar epithelial cells and pulmonary artery endothelial cells has been shown to be particularly useful to examine the pharmacology of invasive pulmonary aspergillosis treatment (Hope et al. 2007a; Gregson et al. 2012; Jeans et al. 2012a,b).”
BackgroundHope, W. W., Drusano, G. L., Moore, C. B., Sharp, A., Louie, A., Walsh, T. J., Denning, D. W., & Warn, P. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00601-06 · Cited by 40 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundAndes, D., Lepak, A., Nett, J., Lincoln, L., & Marchillo, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01305-05 · Cited by 38 · cited 15×
“Most other studies that have attempted to correlate dose, MIC, and outcome with AmB have been hampered by the very narrow MIC and dose range, making it very difficult to correlate the PD indices with outcome (Park et al. 2006).”
BackgroundInfluentialSelf-citationSeyedmousavi, S., Meletiadis, J., Melchers, W. J. G., Rijs, A. J. M. M., Mouton, J. W., & Verweij, P. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00980-12 · Cited by 38 · cited 3×
“The PD studies from preclinical models would suggest that this potential toxicodynamic benefit may negatively impact therapeutic efficacy based on lower Cmax/MIC attainment with a continuous-infusion dosing strategy (Seyedmousavi et al. 2013b).”
BackgroundTe Dorsthorst, D. T. A., Verweij, P. E., Meis, J. F. G. M., Punt, N. C., & Mouton, J. W. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2007-2013.2004 · Cited by 37 · cited 1×
“However, the models provide an opportunity to accurately assess PD characteristics, such as the impact of concentration and can also be useful for estimating the PK/ PD target (Lewis et al. 1998, 2000; Ernst et al. 1999; Te Dorsthorst et al. 2013).”
BackgroundLewis, R. E., & Kontoyiannis, D. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki343 · Cited by 37
Ernst, E. J., Klepser, M. E., & Pfaller, M. A. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00099-6 · Cited by 36 · cited 1×
“Concentration-escalation studies have consistently shown concentration-independent action against Candida species, with maximal growth inhibition at concentrations near the MIC (Ernst et al. 1998, 2002b; Louie et al. 1998; Andes and van Ogtrop 1999; Andes et al. 2003a,b, 2004; Warn et al. 2009).”
BackgroundChaturvedi, V. P., Ramani, R., Ghannoum, M. A., Killian, S. B., Holliday, N. M., Knapp, C. C., Ostrosky-Zeichner, L. L., Messer, S. A., Pfaller, M. A., Iqbal, N. J., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00574-07 · Cited by 36
Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-13 · Cited by 33 · cited 9×
“An additional invivo study has incorporated a wide dose-ranging combination therapy design for invasive aspergillosis (Lepak et al. 2013b).”
BackgroundMethodResultInfluentialSelf-citationLengerová, M., Kocmanová, I., Ráčil, Z., Hrnčířová, K., Pospíšilová, Š., Mayer, J., Najvar, L. K., Wiederhold, N. P., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05356-11 · Cited by 32 · cited 2×
“…(Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al. 2009; Howard et al. 2011; Lengerova et al. 2012; Galiger et al. 2013).”
MethodCuesta, I., Bielza, C., Larrañaga, P., Cuenca‐Estrella, M., Laguna, F., Rodríguez-Pardo, D., Almirante, B., Pahissa, A., & Rodrı́guez-Tudela, J. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00081-09 · Cited by 32
The pharmacology and clinical use of caspofungin
Hope, W. W., Shoham, S., & Walsh, T. J. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.263 · Cited by 32 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundAndes, D. R., Reynolds, D. K., Wart, S. A. V., Lepak, A. J., Kovanda, L. L., & Bhavnani, S. M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01057-13 · Cited by 29 · cited 2×
“Outcomes were statistically similar with both treatment strategies, consistent with animal model studies linking efficacy to the AUC/MIC index (Andes et al. 2013).”
BackgroundResultSelf-citationClemons, K. V., & Stevens, D. A. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000235163.70678.59 · Cited by 29 · cited 1×
“…also exhibit activity against Aspergillus species, and animal model studies show similar PK/PD characteristics including concentration-dependent effects and efficacy linked to AUC/MIC and Cmax/MIC (Wiederhold et al. 2004; Clemons and Stevens 2006; Lewis et al. 2008, 2011; Lepak et al. 2013b).”
BackgroundClinical pharmacodynamics of antifungals
Andes, D. R. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00063-1 · Cited by 29 · cited 2×
“In the context of antifungal drugs, the relevance of protein binding has been shown for both triazoles and echinocandins and will be elucidated in the following sections (Andes 2003a; Andes et al. 2010).”
BackgroundSelf-citationThe eagle-like effect of echinocandins: what’s in a name?
Vanstraelen, K., Lagrou, K., Maertens, J., Wauters, J., Willems, L., & Spriet, I. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.841543 · Cited by 28 · cited 1×
“This observation, though, has not been universally noted for all echinocandins, species, or strains, and mechanistically appears complex (Vanstraelen et al. 2013).”
BackgroundUse of an Animal Model of Disseminated Candidiasis in the Evaluation of Antifungal Therapy
Andes, D. (2005) · Antifungal Agents · doi:10.1385/1-59259-943-5:111 · Cited by 28
Self-citationLivermore, J., Howard, S. J., Sharp, J., Goodwin, J., Gregson, L., Felton, T., Schwartz, J. A., Walker, C., Moser, B., Müller, W., et al. (2014) · mBio · doi:10.1128/mbio.00725-13 · Cited by 27
Elefanti, A., Mouton, J. W., Krompa, K., Al-Saigh, R., Verweij, P. E., Zerva, L., & Meletiadis, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01573-12 · Cited by 27 · cited 1×
“Clinical studies in which echinocandin dose levels have been escalated have not identified a paradoxical effect (Pappas et al. 2007; Betts et al. 2009; Shields et al. 2011; Szilagyi et al. 2012; Andes et al. 2013; Elefanti et al. 2013).”
BackgroundHope, W. W., Warn, P. A., Sharp, J., Reed, P., Keevil, B. G., Louie, A., Walsh, T. J., Denning, D. W., & Drusano, G. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00488-07 · Cited by 24 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundManosuthi, W., Chetchotisakd, P., Nolen, T., Wallace, D., Sungkanuparph, S., Anekthananon, T., Supparatpinyo, K., Pappas, P., Larsen, R., Filler, S., et al. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00778.x · Cited by 23 · cited 1×
“The relationship between PK and outcome was significant and favored the 800-mg/d-dosing regimen (Manosuthi et al. 2010).”
BackgroundSelf-citationThe Effects of an Hsp90 Inhibitor on the Paradoxical Effect
Kaneko, Y., Ohno, H., Imamura, Y., Kohno, S., & Miyazaki, Y. (2009) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2009.392 · Cited by 23 · cited 2×
“…phenomenon include protein kinase C (Wiederhold et al. 2005; Shields et al. 2011), the calcineurin pathway (Wiederhold et al. 2005; Shields et al. 2011), the high-osmolarity glycerol response pathway (Popolo et al. 2001), and heat shock protein 90 (Cowen and Lindquist 2005; Kaneko et al. 2009).”
BackgroundLewis, R. E., Liao, G., Hou, J., Prince, R. A., & Kontoyiannis, D. P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr142 · Cited by 23 · cited 1×
“…also exhibit activity against Aspergillus species, and animal model studies show similar PK/PD characteristics including concentration-dependent effects and efficacy linked to AUC/MIC and Cmax/MIC (Wiederhold et al. 2004; Clemons and Stevens 2006; Lewis et al. 2008, 2011; Lepak et al. 2013b).”
BackgroundVitale, R. G., Meis, J. F. G. M., Mouton, J. W., & Verweij, P. E. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg285 · Cited by 22 · cited 2×
“In vitro and animal model PD time-kill studies against Candida and filamentous fungi have shown concentration-dependent action as drug dose is escalated multiple times above the MIC (Turnidge et al. 1994; Kelpser et al. 1997; Denning and Warn 1999; Ernst et al. 2000, 2002b; Groll et al. 2000; Warn et al. 2000; Andes e…”
BackgroundWarn, P. A., Morrissey, J., Moore, C. B., & Denning, D. W. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2664-2671.2000 · Cited by 22 · cited 2×
“In vitro and animal model PD time-kill studies against Candida and filamentous fungi have shown concentration-dependent action as drug dose is escalated multiple times above the MIC (Turnidge et al. 1994; Kelpser et al. 1997; Denning and Warn 1999; Ernst et al. 2000, 2002b; Groll et al. 2000; Warn et al. 2000; Andes e…”
BackgroundGavaldà, J., Martín-Gómez, M. T., López, P., Gomis, X., Ramírez, J. L., Rodríguez-Pardo, D., Len, Ó., Puigfel, Y., Ruíz-Camps, I., & Pahissa, A. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01262.x · Cited by 22 · cited 1×
“…multiple times above the MIC (Turnidge et al. 1994; Kelpser et al. 1997; Denning and Warn 1999; Ernst et al. 2000, 2002b; Groll et al. 2000; Warn et al. 2000; Andes et al. 2001, 2006; Vitale et al. 2003; Gavalda et al. 2005; Lewis et al. 2005; Wiederhold et al. 2006; Seyedmousavi et al. 2013a).”
BackgroundWiederhold, N. P., Najvar, L. K., Vallor, A. C., Kirkpatrick, W. R., Bocanegra, R. A., Molina, D. K., Olivo, M., Graybill, J. R., & Patterson, T. F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01425-07 · Cited by 21 · cited 2×
“…(Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al. 2009; Howard et al. 2011; Lengerova et al. 2012; Galiger et al. 2013).”
BackgroundSzilágyi, J., Földi, R., Bayegan, S., Kardos, G., & Majoros, L. (2012) · Journal of Chemotherapy · doi:10.1179/1120009x12z.0000000005 · Cited by 21 · cited 2×
“A confirmatory study design showed abolition of the paradoxical effect following the addition of a chitin synthase inhibitor to echinocandin therapy (Shields et al. 2011; Szilagyi et al. 2012).”
BackgroundIkawa, K., Nomura, K., Morikawa, N., Ikeda, K., & Taniwaki, M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp298 · Cited by 20 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundHope, W. W., Warn, P. A., Sharp, J., Reed, P., Keevil, B. G., Louie, A., Denning, D. W., & Drusano, G. L. (2005) · The Journal of Infectious Diseases · doi:10.1086/432069 · Cited by 20
Demchok, J. P., Meletiadis, J., Roilides, E., & Walsh, T. J. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01700.x · Cited by 18
Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia
Arendrup, M. C., Cuenca‐Estrella, M., Donnelly, J. P., Lass‐Flörl, C., & Rodríguez-Tudela, J. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-08 · Cited by 18 · cited 4×
“Although clinical PK/PD data sets are in general uncommon, there is a relatively large experience with fluconazole and voriconazole (Rex et al. 1997; Lee et al. 2000; Takakura et al. 2004; Clancy et al. 2005; Pfaller et al. 2006; Pai et al. 2007; Rodrı́guez-Tudela et al. 2007; Baddley et al. 2008).”
BackgroundResultInfluentialEfficacy and Safety of Generic Amphotericin B in Experimental Pulmonary Aspergillosis
Petraitis, V., Petraitienė, R., Lin, P., Calis, K. A., Kelaher, A. M., Muray, H. A., Mya-San, C., Mickiene, D., Bacher, J. D., & Walsh, T. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1642-1645.2005 · Cited by 17
Petraitis, V., Petraitienė, R., Solomon, J. M., Kelaher, A. M., Murray, H. A., Mya-San, C., Bhandary, A. K., Sein, T., Avila, N. A., Basevičius, A., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1510-1517.2006 · Cited by 16 · cited 1×
“Examples include measurement of fungal cell wall component (galactomannan and b-glucan), pulmonary imaging, histopathology, and lung weight (Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et…”
BackgroundEfficacy of micafungin for the treatment of candidemia
Andes, D. R., & Safdar, N. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0025-7 · Cited by 15
Self-citationAl-Nakeeb, Z., Sudan, A., Jeans, A. R., Gregson, L., Goodwin, J., Warn, P. A., Felton, T., Howard, S. J., & Hope, W. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00141-12 · Cited by 15 · cited 1×
“This model has also been valuable in examining novel methods of drug delivery via 2 Cite this article as Cold Spring Harb Perspect Med 2015;5:a019653 w w w .p er sp ec ti ve si n m ed ic in e. o rg nebulized or airway route (Al-Nakeeb et al. 2012).”
MethodNew drugs for the systemic mycoses: flucytosine and clotrimazole.
Jp, U. (1975) · Europe PMC (PubMed Central) · Cited by 12
Diagnostic imaging of experimental invasive pulmonary aspergillosis
Walsh, T. J., Petraitis, V., Petraitienė, R., Solomon, J. M., Bacher, J. D., Greene, L., Cotton, M. P., Groll, A. H., Roilides, E., Avila, N. A., et al. (2009) · Medical Mycology · doi:10.1080/13693780802665879 · Cited by 10 · cited 2×
“…(Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al. 2009; Howard et al. 2011; Lengerova et al. 2012; Galiger et al. 2013).”
BackgroundTroke, P. F., Hockey, H. P., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05771-11 · Cited by 10 · cited 1×
“The sole study that includes analysis of PK, MIC, and outcome is with voriconazole (Troke et al. 2011).”
BackgroundIn Vitro Model of Invasive Pulmonary Aspergillosis in the Human Alveolus
Gregson, L., Hope, W. W., & Howard, S. J. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-539-8_24 · Cited by 9 · cited 1×
“For example, a human cell culture with a bilayer of alveolar epithelial cells and pulmonary artery endothelial cells has been shown to be particularly useful to examine the pharmacology of invasive pulmonary aspergillosis treatment (Hope et al. 2007a; Gregson et al. 2012; Jeans et al. 2012a,b).”
BackgroundAssessment of the Paradoxical Effect of Caspofungin in Therapy of Candidiasis
Clemons, K. V., Espiritu, M., Parmar, R., & Stevens, D. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00694-06 · Cited by 6
Seyedmousavi, S., Mouton, J. W., Verweij, P. E., & Andes, D. R. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0668le · Cited by 4 · cited 3×
“The PD studies from preclinical models would suggest that this potential toxicodynamic benefit may negatively impact therapeutic efficacy based on lower Cmax/MIC attainment with a continuous-infusion dosing strategy (Seyedmousavi et al. 2013b).”
BackgroundSelf-citationProtein binding of antibiotics does affect their antistaphyloccal activity
Kunin, C. M. (1986) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/17.2.263 · Cited by 4
Hall, P. S., Kennedy, G., Morton, J., Hill, G. R., & Durrant, S. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2005.00847.x · Cited by 2 · cited 2×
“The latter toxicodynamic concept has also been further examined clinically with a suggestion of reduced renal toxicity when amphotericin B has been administered as a continuous infusion compared with once-daily bolus dosing (Eriksson et al. 2001; Imhof et al. 2003; Peleg and Woods 2004; Hall et al. 2005).”
Background
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Aspergillus fumigatus and aspergillosis: From basics to clinics
Arastehfar, A., Carvalho, A., Houbraken, J., Lombardi, L., Garcia-Rubio, R., Jenks, J. D., Rivero-Menendez, O., Aljohani, R., Jacobsen, I. D., Berman, J., et al. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100115 · Cited by 241
Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy
Wall, G., & Lopez-Ribot, J. L. (2020) · Antibiotics · doi:10.3390/antibiotics9080445 · Cited by 176
“Readers are referred to excellent reviews on these topics [50,51].”
BackgroundIdentification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J. B., Ojima, I., Bullesbach, E., et al. (2015) · mBio · doi:10.1128/mbio.00647-15 · Cited by 144
“and interact with other drugs such as chemotherapy agents and immunosuppressants (4).”
BackgroundDefining the frontiers between antifungal resistance, tolerance and the concept of persistence
Delarze, E., & Sanglard, D. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.001 · Cited by 118
Metadata
- Authors
- Lepak, A. J., & Andes, D. R.
- Affiliations
- University of Wisconsin–Madison (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-11-10
- Volume
- 5
- Issue
- 5
- Pages
- a019653-a019653
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC4448584
- OpenAlex
- W2106743979
- Cited by
- 134
- References
- 250
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 14 · 2023: 19 · 2022: 13 · 2021: 13 · 2020: 17 · 2019: 13 · 2018: 5 · 2017: 8 · 2016: 2 · 2015: 3
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal agents, pharmacokinetics, pharmacodynamics, pharmacokinetic-pharmacodynamic modeling, polyenes, 5-fluorocytosine, azoles, echinocandins, dosing regimen, susceptibility breakpoints, combination antifungal therapy, drug toxicity
- MeSH terms
- Animals, Antifungal Agents, Disease Models, Animal, Flucytosine, Humans, Mycoses, Polyenes, Rabbits, Triazoles, Mice, Rats, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.